300 results
Page 4 of 15
8-K
EX-10.1
ffw5dcymtg5o774
21 Dec 20
Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board
4:18pm
8-K
EX-99.1
ov09 1xs5bb9exrq51
7 Dec 20
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
1:22pm
8-K
EX-99.1
2xbpqkoq8l
5 Nov 20
Cardiff Oncology Announces Third Quarter 2020 Results and Highlights
4:09pm
8-K
EX-99.1
zodeq
20 Oct 20
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
11:59am
8-K
EX-99.1
vtdu8 p28dqm
30 Sep 20
Cardiff Oncology Announces Proposed Public Offering
4:09pm
8-K
EX-99.2
3wky5m1ak2malm
30 Sep 20
Cardiff Oncology Announces Proposed Public Offering
4:09pm
8-K
EX-99.1
gpuxj5
22 Sep 20
Regulation FD Disclosure
12:00am
8-K
EX-99.1
ip3ib19
17 Sep 20
Other Events
11:18am
8-K
EX-99.1
acovs00
15 Sep 20
Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial
10:36am
8-K
EX-99
2exa7cpf
14 Sep 20
Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients
11:55am
8-K
EX-99.1
ajuoo
11 Aug 20
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
4:04pm
8-K
EX-10.1
gy7vz2wl lh
16 Jun 20
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
4:26pm
8-K
EX-99.1
h7s64m0v33g3dqitiri
16 Jun 20
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
4:26pm
8-K
EX-3.1
vm3nhtwy vetk
16 Jun 20
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
4:26pm
8-K
EX-99.1
g16403 gb
15 Jun 20
Other Events
11:50am
8-K
EX-99.1
4cmhq i8ahjb761
9 Jun 20
Other Events
11:26am
8-K
EX-99.1
c1i tpxd19
29 May 20
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
12:00pm
8-K
EX-99.1
40rt25nfnm5 bynb92e
28 May 20
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
11:50am